Follow-up study on serum cholesterol profiles and potential sequelae in recovered COVID-19 patients

作者：Guiling Li, Li Du, Xiaoling Cao, Xiuqi Wei, Yao Jiang, Yuqi Lin, Vi Nguyen, Wenbin Tan, Hui Wang · 发表于：BMC Infectious Diseases · 年份：2021 · DOI：10.1186/s12879-021-05984-1 · 被引用次数：42 · 研究领域：COVID-19 Clinical Research Studies、Long-Term Effects of COVID-19、Pharmacological Receptor Mechanisms and Effects

BACKGROUND: COVID-19 patients develop hypolipidemia. However, it is unknown whether lipid levels have improved and there are potential sequlae in recovered patients. OBJECTIVE: In this follow-up study, we evaluated serum lipidemia and various physiopathological laboratory values in recovered patients. METHODS: A 3-6 month follow-up study was performed between June 15 and September 3, 2020, to examine serum levels of laboratory values in 107 discharged COVID-19 patients (mild = 59; severe/critical = 48; diagnoses on admission). Sixty-one patients had a revisit chest CT scan. A Wilcoxon signed-rank test was used to analyze changes in laboratory values at admission and follow-up. RESULTS: LDL-c and HDL-c levels were significantly higher at follow-up than at admission in severe/critical cases (p < 0.05). LDL-c levels were significantly higher at follow-up than at admission in mild cases (p < 0.05). Coagulation and liver functional values were significantly improved at follow-up than at admission for patients (p < 0.05). Increases in HDL-c significantly correlated with increases in numbers of white blood cells (p < 0.001) during patients' recovery. With exclusion of the subjects taking traditional Chinese medicines or cholesterol-lowering drugs, LDL-c and HDL-c levels were significantly increased at follow-up than at admission in severe/critical cases (p < 0.05). Residue lesions were observed in CT images in 72% (44 of 61) of follow-up patients. CONCLUSIONS: Improvements of LDL-c,...